Drug Trial Radar · NCT00607074
Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in Bangladesh
Last checked: Nov 20, 2026Latest source record: Feb 5, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
410
Actual
Start
Jun 2003
Primary completion
Apr 2004
Study completion Dec 2006
Sponsor
- Lead sponsor
- University of CambridgeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 5, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 3 months, up to 15 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This longitudinal study aimed to assess whether regular anti-Giardia and antihelmintic treatment improved growth and small intestinal mucosal function of rural Bangladeshi infants.
Conditions
- Giardiasis
Interventions
Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)Drug
Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)
Anti-Giardia treatment only (secnidazole or albendazole)Drug
Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole
Control group (placebo)Drug
Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- nutritional statusTime frame: 9 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institute of Preventive and Social Medicine
Mohakhali, Dhaka Division, Bangladesh
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.